Jusmin Patel, MD
Nephrology · Reno, NVNPI 1518259647
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Lilly USA, LLC at 28.2% of the total. Among nephrology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 536 payments — averaging $80.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$12K
- Boehringer Ingelheim$9K
- Novartis$7K
- Vifor Pharma, Inc.$7K
- Amgen$1K
- OPKO Pharmaceuticals, LLC$1K
- plus $5K from 29 others
Across 79 payments — averaging $1471.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$44K
- Travere Therapeutics, Inc.$26K
- Hoffmann-la Roche Limited$25K
- Boehringer Ingelheim$11K
- Boehringer Ingelheim International GmbH$6K
- Eli Lilly$4K
What the payments were for
- Consulting fees$5,50013%
- Speaking & faculty fees$25,24358%
- Travel & lodging$2,6506%
- Food & beverage$9,13721%
- Education$8772%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 14 | $12,236 |
| Boehringer Ingelheim | 21 | $8,968 |
| Novartis | 18 | $7,376 |
| Vifor Pharma, Inc. | 32 | $6,889 |
| Amgen(2 entities) | 52 | $1,249 |
| OPKO Pharmaceuticals, LLC | 116 | $1,204 |
| AstraZeneca(2 entities) | 32 | $934 |
| Calliditas Therapeutics US Inc. | 66 | $742 |
| Otsuka America Pharmaceutical, Inc. | 43 | $658 |
| Bayer | 29 | $584 |
| GSK | 22 | $483 |
| Travere Therapeutics, Inc. | 21 | $464 |
| ANI Pharmaceuticals, Inc. | 11 | $217 |
| Aurinia Pharma U.S., Inc. | 8 | $177 |
| Daiichi Sankyo Inc. | 7 | $146 |
| Renalytix AI, Inc. | 4 | $137 |
| Tactile Systems Technology Inc | 3 | $121 |
| Mallinckrodt Hospital Products Inc. | 5 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $101 |
| Ardelyx, Inc. | 4 | $94 |
| Mallinckrodt Enterprises LLC | 1 | $75 |
| Fresenius USA Marketing, Inc. | 3 | $67 |
| Akebia Therapeutics Inc | 4 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Abbott | 2 | $39 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Sanofi | 2 | $36 |
| Recordati_rare_diseases_inc. | 1 | $26 |
| Novo Nordisk | 1 | $26 |
| Medtronic | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Cormedix Inc. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $17 |
| Amicus Therapeutics, Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,407 in reported general payments places this provider in the 95th percentile of 125 nephrology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 13 | $256,608 |
| FarxigaDapagliflozin Propanediol | 112 | $123,603 |
| JardianceEmpagliflozin | 49 | $66,253 |
| XphozahTenapanor Hcl | 12 | $34,948 |
| KerendiaFinerenone | 27 | $32,928 |
| Sevelamer Carbonate | 33 | $7,497 |
| Cinacalcet Hcl | 33 | $3,674 |
| ProsolParenteral Amino Acid 20% No.1 | 14 | $1,912 |
| Valsartan | 75 | $1,694 |
| Calcitriol | 48 | $951 |
| Losartan Potassium | 44 | $486 |
| Allopurinol | 60 | $378 |
| Furosemide | 55 | $334 |
| Tamsulosin Hcl | 13 | $153 |
| Atorvastatin Calcium | 15 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $658 | $256,60813 claims |
| AstraZenecaFarxiga | $934 | $123,603112 claims |
| Boehringer IngelheimJardiance | $8,968 | $66,25349 claims |
| BayerKerendia | $584 | $32,92827 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $217 | $1,69475 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 125 nephrology providers in Nevada.
Other nephrology in Reno
- Mukesh SharmaReno$15K
- Javier NarvarteReno$6K
- Arika GuptaReno$6K
- James SullivanReno$4K
- Iryna PatelReno$4K
- Robert QuigleyReno$4K
- Ridhmi RajapakseReno$3K
- Soni DhanireddyReno$2K
- Sunil SkariaReno$2K
- Joseph DoanReno$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.